Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Abandoned drugs
Farglitazar
Другие языки:

    Farglitazar

    Подписчиков: 0, рейтинг: 0
    Farglitazar
    Farglitazar.svg
    Clinical data
    Pregnancy
    category
    • N/A
    ATC code
    • none
    Legal status
    Legal status
    • Development discontinued
    Identifiers
    • N-(o-Benzoylphenyl)-O-[2-(5-methyl- 2-phenyl-4-oxazolyl)ethyl]-L-tyrosine
    CAS Number
    PubChem CID
    IUPHAR/BPS
    ChemSpider
    UNII
    KEGG
    ChEMBL
    CompTox Dashboard (EPA)
    Chemical and physical data
    Formula C34H30N2O5
    Molar mass 546.623 g·mol−1
    3D model (JSmol)
    • O=C(c1ccccc1)c2ccccc2N[C@H](C(=O)O)Cc5ccc(OCCc3nc(oc3C)c4ccccc4)cc5
    • InChI=1S/C34H30N2O5/c1-23-29(36-33(41-23)26-12-6-3-7-13-26)20-21-40-27-18-16-24(17-19-27)22-31(34(38)39)35-30-15-9-8-14-28(30)32(37)25-10-4-2-5-11-25/h2-19,31,35H,20-22H2,1H3,(H,38,39)/t31-/m0/s1 ☒N
    • Key:ZZCHHVUQYRMYLW-HKBQPEDESA-N ☒N
     ☒NcheckY (what is this?)  (verify)

    Farglitazar is a peroxisome proliferator-activated receptor agonist which was formerly under development by GlaxoSmithKline, but has never been marketed. It progressed to phase II clinical trials for the treatment of hepatic fibrosis, but failed to show efficacy. After reaching phase III for type 2 diabetes, further development was discontinued.


    Новое сообщение